Procaps Gr Q3 Sales $110.00M

Procaps Gr (NASDAQ:PROC) reported quarterly sales of $110.00 million which missed the analyst consensus estimate of $123.90 million by 11.22 percent.

Procaps Gr (NASDAQ:PROC) reported quarterly sales of $110.00 million which missed the analyst consensus estimate of $123.90 million by 11.22 percent.

Total
0
Shares
Related Posts
Read More

Sorrento Reports Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept; Says Achieving Improvements In Rheumatoid Arthritis Disease Measures At 50% Of Standard Dose For Patients (7 of 7) With Inadequate Response To Subcuta

Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements

SRNE